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ABT-737 as a case study to foresee the
complexities of personalized medicine
Vasileios A Stamelos1, Charles W Redman2 and Alan Richardson1*Abstract
BH3 mimetics such as ABT-737 and navitoclax bind to the BCL-2 family of proteins and induce apoptosis through
the intrinsic apoptosis pathway. There is considerable variability in the sensitivity of different cells to these drugs.
Understanding the molecular basis of this variability will help to determine which patients will benefit from these
drugs. Furthermore, this understanding aids in the design of rational strategies to increase the sensitivity of cells
which are otherwise resistant to BH3 mimetics. We discuss how the expression of BCL-2 family proteins regulates
the sensitivity to ABT-737. One of these, MCL-1, has been widely described as contributing to resistance to ABT-737
which might suggest a poor response in patients with cancers that express levels of MCL-1. In some cases,
resistance to ABT-737 conferred by MCL-1 is overcome by the expression of pro-apoptotic proteins that bind to
apoptosis inhibitors such as MCL-1. However, the distribution of the pro-apoptotic proteins amongst the various
apoptosis inhibitors also influences sensitivity to ABT-737. Furthermore, the expression of both pro- and
anti-apoptotic proteins can change dynamically in response to exposure to ABT-737. Thus, there is significant
complexity associated with predicting response to ABT-737. This provides a paradigm for the multiplicity of intricate
factors that determine drug sensitivity which must be considered for the full implementation of personalized
medicine.
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The concept of personalized medicine envisages that ther-
apy is tailored to take into account in each patient the
pharmacodynamic and pharmacokinetic factors which
may affect drug safety and efficacy. In oncology, this dif-
fers from the traditional approach in which the therapy is
often based on the tissue of origin of the tumor. In perso-
nalized medicine, a treatment is chosen to address the
molecular defects associated with the patient’s personal
disease. In principle, it appears relatively straightforward
to identify genetic (or epigenetic) abnormalities in a
patient’s cancerous cells and select therapy accordingly.
However, simply knowing the genes affected may be inad-
equate without a detailed understanding of the regulation* Correspondence: a.richardson1@keele.ac.uk
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reproduction in any medium, provided the orof the signalling pathways involved. An often quoted ex-
ample is provided by cetuximab, a therapeutic antibody
which targets the EGF receptor. Cetuximab is effective
in colon cancer driven by activation of the EGF pathway
but less efficacious in patients whose tumors also are
activated downstream of the EGF receptor by mutation
of the gene encoding RAS. Furthermore, understanding
signalling pathways in detail allows the rational design
of drug combinations. We anticipate that a full imple-
mentation of personalized medicine will require pro-
found analysis of the signalling pathways involved in the
drug response. We exemplify this argument by a discus-
sion of ABT-737, together with its cogener Navitoclax
(ABT-263). ABT-737 is a “tool” compound that has been
widely used, whereas ABT-263 possesses superior oral
bioavailability and is currently being evaluated in clinical
trials. The efficacy of these drugs depends on their abil-
ity to activate the intrinsic apoptosis pathway which we
review first.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The increase in oncogenic signalling (oncogene stress)
and the DNA damage that occurs in genetically unstable
cancer cells generate pro-apoptotic signals which, if exe-
cuted, would effectively curtail tumorigenesis. Cancer
cells are obliged by selective pressure to evolve mechan-
isms which suppress these pro-apoptotic signals. This
has led to the ability of tumor cells to evade cell death
through apoptosis being recognised as one of the hall-
marks of cancer [1]. The dependency of cancer cells on
the pathways suppressing apoptosis provides a thera-
peutic strategy for the treatment of cancer, because
agents that inactivate these pathways should cause cell
death. There are two key apoptosis pathways. The ex-
trinsic apoptosis pathway is activated by extracellular
pro-apoptotic stimuli, whereas the intrinsic pathway
responds to intracellular cues. The intrinsic apoptosis
pathway is controlled by the BCL-2 family of proteins
(Table 1). This family comprises several classes of pro-
teins which are considered as “effectors” (BAX, BAK),
“inhibitors” (BCL-2, BCL-XL, BCL-2 MCL-1, BFL/A1,
BCL-B), “activators” (BIM, BID, PUMA [2-4], possibly
BMF and NOXA [5]) and “sensitizers” (eg BAD, BMF,
NOXA). The family share several conserved “BH”
domains termed BH1, BH2, BH3 and BH4. Of these
domains, the activators and the sensitizers possess only
the BH3 domain, and hence are often referred to as
“BH3-only” proteins. These proteins are induced by cel-
lular stress, e.g. chemotherapy. The other family mem-
bers possess BH1, 2, 3 and 4 domains. The inhibitors are
consequently referred to as multi-domain apoptosis inhi-
bitors. For clarity, we shall refer to these as “apoptosis
inhibitors” throughout this review, but these should notTable 1 BCL-2 family proteins
BH3 only
pro-apoptotic proteins
Multi-domain
pro-apoptotic
Anti-apoptotic
proteins
Activators
BIM BAK BCL-2
BID BAX BCL-XL
PUMA BOK BCL-W
MCL-1
Sensitizers BFL/BCL-2A1
NOXA BCL-B
BAD
BMF
HRK
BIK
BNIP3
Of the BH3 only proteins, BID, BIM and possibly PUMA are considered
apoptosis activators and the others as apoptosis sensitizers. BOK is an
apoptosis effector expressed primarily in the ovary.be confused with other inhibitors of apoptosis that are
not part of the BCL-2 family. These multi-domain pro-
teins possess a hydrophobic groove that serves as a
binding site for BH3 domains. BAX and BAK can form
homo-oligomers that form a pore in the mitochondrial
outer membrane. This allows the release of several
mediators of apoptosis including cytochrome C, trig-
gering the subsequent activation of caspases. BAK nor-
mally resides in the mitochondrial outer membrane,
whereas BAX translocates from the cytosol to mito-
chondria following activation. Two competing models
have been proposed for how BAX and BAK are acti-
vated, but recent data supports a “direct activation”
model in which the activator BH3-only proteins bind
directly but transiently to BAX or BAK to activate
them [3]. The ability of the activator BH3-only proteins
to trigger BAK and BAX is restrained by the apoptosis
inhibitors which sequester the BH3-only activators by
binding to their BH3 domain. The apoptosis inhibitors
can also suppress apoptosis by binding to the BH3 do-
main of the effectors and have been shown in the case
of BCL-XL to promote the translocation of BAX from
mitochondria to the cytosol [6]. However, the apoptosis
inhibitors may be prevented from suppressing apop-
tosis by the BH3-only sensitizers whose BH3 domain
can also bind to the apoptosis inhibitors. The BH3-
only sensitizers occupy the inhibitors, reducing the
capacity of the apoptosis inhibitors to sequester the
BH-3 only activators or the effectors (Figure 1). Thus,
the BH3-only sensitizers reduce the reservoir of unli-
ganded inhibitors available to suppress apoptosis, facili-
tating pro-apoptotic signalling to BAK and BAX by the
BH3-only activators. The alternative “indirect” model
envisages that the apoptosis inhibitors sequester the
effectors. In this model, the effectors are not consid-
ered to require activation, but are continually repressed
by the apoptosis inhibitors. The BH3-only proteins in-
duce apoptosis indirectly by liberating the effectors
from the apoptosis inhibitors. Variations on both these
models have been proposed and it is possible that
aspects of both are correct.
A further layer of complexity is involved because of
the different binding specificity of the apoptosis inhibi-
tors for their ligands (Figure 2). Some BH3-only proteins
can bind to all the apoptosis inhibitors, whereas other
BH3-only proteins exhibit specificity for a subset of the
apoptosis inhibitors. For example, BAD bind preferen-
tially to BCL-2, BCL-XL and BCL-w [7,8], whereas
NOXA binds preferentially to MCL-1 [7,8] and possibly
BFL/A1 [7]. The BH3-only apoptosis activators BIM and
PUMA are each able to bind to all the apoptosis inhibi-
tors whereas BID has a more restricted binding profile
[7,9]. Whether the induction of a BH3-only protein leads
to apoptosis depends on whether the repertoire of
Figure 1 The intrinsic apoptosis pathway. Apoptosis is triggered by the formation of a pore in the mitochondrial outer membrane formed
from the effectors. This is controlled by the activator molecules (BID, BIM, PUMA, labelled “A”) which directly stimulate the effectors (BAK and
BAX). A pro-apoptotic signal (such as oncogene stress or chemotherapy) induces the expression of apoptosis activators and sensitizers. The
activators may be sequestered by the inhibitors (labelled “I”, e.g. BCL-2, BCL-XL, MCL-1) and this prevents apoptosis. However, sensitizer molecules
(labelled “S”, eg NOXA, BAD) or BH3 mimetics (eg ABT-737, labelled “ABT”) can occupy the inhibitors, preventing them from binding the
activators. In cells in which the inhibitors are already primed with an activator, the effective displacement of the activator from the inhibitor by
ABT-737 induces apoptosis.
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the pro-apoptotic signal arising from the activation of
BH3-only proteins.
ABT-737 and other BH3 mimetics
The recognition that BCL-2 family proteins regulate
apoptosis has led to the development of “BH3 mimetics”,
drugs which compete with BH3 domains to bind the
apoptosis inhibitors. These drugs function as sensitizer
molecules – although unable to directly stimulate apop-
tosis, they prevent the apoptosis inhibitors from seques-
tering the pro-apoptotic proteins through their BH3Figure 2 Binding specificity of BH3 only proteins. The activators (denot
(denoted with an “I”). However, tBID and the sensitizers (denoted with a “S
discrepancies in the literature (e.g., whether BMF binds MCL-1) and it is imp
from [7-9] in a binary fashion (interaction or no interaction) whereas in rea
affinities.domains (reviewed in [10]). In cells where the apoptosis
inhibitors are already bound to a BH3-only apoptosis ac-
tivator, the cell are considered “primed for death” be-
cause this allows a BH3 mimetic to induce apoptosis
through liberation of a BH3-only activator (Figure 1).
BH3 mimetics have shown remarkable single agent ac-
tivity in primed cells [8] which appear addicted to apop-
tosis inhibitors for survival. In cells where the apoptosis
inhibitors are not already primed with a BH3-only acti-
vator, exposure to chemotherapeutic agents induces
BH3-only proteins that can be liberated from the inhibi-
tors by a BH3 mimetic. Consequently, BH3 mimeticsed with an “A”), BIM and PUMA bind to all the apoptosis inhibitors
”) bind to a subset of the apoptosis inhibitors. There are some
ortant to note that this diagram summarizes interactions (adapted
lity the interactions are better described by a range of binding
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peutic agents.
Several BH3 mimetics have been described. The best
characterized is probably ABT-737 [11] and its analogue
ABT-263 [12]. These compounds bind with high affinity
to BCL-2, BCL-XL and BCL-W but weakly to MCL-1
and BFL/A1. ABT-737 can induce apoptosis in cells in
which the apoptosis inhibitors are primed with BH3-
only activator proteins and ABT-737. Chemotherapeutic
agents may induce priming, and consequently ABT-737
and ABT-263 are synergistic with several different che-
motherapeutic agents [10,13]. Whilst the activity of
ABT-737 is substantially reduced in cells lacking BAX or
BAK, several BH3 mimetics other than ABT-737 retain
cytotoxicity in BAX−/−/BAK−/− cells [14,15] and unex-
pectedly increase the level of NOXA [16]. This suggests
that the BH3 mimetics other than ABT-737 and ABT-
263 possess additional activities that have yet to be fully
defined. As the goal of this review is to summarize what
determines sensitivity to BH3 mimetics, this undefined
pharmacological activity significantly complicates a ra-
tional discussion of the factors that determine sensitivity
to these drugs. Thus, this review will focus on ABT-737
(and ABT-263).
Determinants of sensitivity to ABT-737
Knowledge of the tissue of origin of the malignant cells
is not redundant, even in the era of personalized medi-
cine, because some genetic aberrations are commonly
associated with a particular cancer. For example, BCL-2
is commonly amplified in chronic lymphocytic leukemia
(CLL). However, the fact that cancer is a disease involv-
ing significant genetic instability means that cancer cells
sharing the same tissue origin may be genetically quite
distinct. The genetic background of malignant cells can
have a profound effect on drug response. Indeed, cancers
of different tissue origins may share similar pharmaco-
logical sensitivities because they share common genetic
anomalies. For example, chronic myelogenous leukemia
and non-small cell lung cancer patients may share a
polymorphism in the gene encoding BIM which leads to
reduced expression of BIM isoforms possessing the BH3
domain that is necessary for its pro-apoptotic activity.
Cells with this polymorphism are resistant to tyrosine
kinase inhibitors, but this can be overcome with ABT-
737 [17].
BCL-2, BCL-XL and BCL-W
The most obvious determinant of sensitivity to any drug
is whether cells express the intended targets. In the case
of ABT-737, these are BCL-2, BCL-XL and BCL-W. It is
often assumed that increased expression of an oncogene
indicates a tumor cell’s dependence on it. Elevated ex-
pression of these apoptosis inhibitors may be necessaryto tolerate elevated levels of BH3-only proteins. How-
ever, the situation is significantly more complex, because
the expression of BCL-2, BCL-XL or BCL-W is a neces-
sary but not a sufficient condition to confer drug sensi-
tivity [18,19]. Cells in which the apoptosis inhibitors are
already primed with BH3-only proteins provide an ex-
ample of oncogene addiction and are particularly sensi-
tive to ABT-737. In contrast, cells in which BCL-2,
BCL-XL or BCL-W are expressed but which are unoccu-
pied by either BH3-only proteins or by BAX or BAK are
not likely to be sensitive to ABT-737. Thus, measure-
ment of expression levels of BCL-2, BCL-XL and
BCL-W alone may be a poor predictor of sensitivity.
An added complication has recently arisen because at
least two groups have noted a discrepancy between the
activity of ABT-737 expected from in vitro experiments
and that observed in live cells. The binding profile of
ABT-737 suggests that it should inhibit the binding of
BH3-only proteins to BCL-2, BCL-XL or BCL-W. How-
ever, in cells ABT-737 appears to more readily prevent
BIM from binding to BCL-2 than to BCL-XL or BCL-W
[20]. This might reflect the somewhat lower affinity of
BIM for BCL-2. Another report suggests that the inter-
action of BIM with BCL-2 or BCL-XL is altered by the
subcellular localization of the complex, and mitochon-
drial BIM complexes with BCL-2 or BCL-XL are rela-
tively insensitive to ABT-737 [21]. These observations
are particularly relevant to personalized medicine, be-
cause it underscores the difficulty in making predictions
of drug sensitivity using measurement of protein expres-
sion and knowledge of binding interactions measured
in vitro.
MCL-1 and BFL/A1
Several lines of evidence indicate that MCL-1 confers re-
sistance to ABT-737 because of the poor affinity of
ABT-737 for MCL-1. Silencing MCL-1 by RNA interfer-
ence increases the sensitivity of several cancer cell lines
to ABT-737 [22-32] while ectopic expression of MCL-1
can render cells resistant to ABT-737 [24,29,33]. Simi-
larly, prolonged exposure to ABT-737 to render cells re-
sistant to ABT-737 leads to the up-regulation of MCL-1
[34]. Short-term exposure to ABT-737 has also been
reported to elevate expression of MCL-1 [16,35,36].
However, expression of MCL-1 is not always sufficient
to cause resistance to ABT-737 because occupancy of
MCL-1 by pro-apoptotic proteins can effectively inacti-
vate MCL-1 [18,37] (and see below). In the context of
personalized medicine, this argues that expression of
MCL-1 on its own should not necessarily preclude the
use of ABT-263.
It also noteworthy that some cells appear to be more
dependent on MCL-1 for survival rather than on other
BCL-2 family members [38], and these cells may be
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toclax”[39]. By causing the degradation of MCL-1, this
compound has the potential to overcome some forms of
resistance to ABT-737, and has shown synergy with
ABT-737 [39].
Expression of BFL1/A1 may also contribute to the sen-
sitivity of cells to ABT-737 because, like MCL-1, BFL/A1
does not bind to ABT-737 with high affinity. Knockdown
of BFL/A1 increases sensitivity to ABT-737 [27] whereas
BFL/A1 over-expression reduces sensitivity [40]. Resist-
ance to ABT-737 may also lead to up-regulation of
BFL1/A1 [34].
NOXA
The observation that MCL-1 and BFL/A1 can confer re-
sistance to ABT-737 suggests that BH3-only proteins
that occupy these apoptosis inhibitors should increase
sensitivity to ABT-737.
NOXA is particularly significant because it binds to
both MCL-1 and BFL/A1, the apoptosis inhibitors impli-
cated in resistance to ABT-737. Ectopic expression of
NOXA has been shown to increase sensitivity to ABT-
737 [26,32,41], whereas inhibition of NOXA expression
by RNA interference decreases sensitivity to ABT-737
[40,41]. By blocking MCL-1, NOXA prevents MCL-1
from sequestering BH3-only proteins that are released
from other BCL-2 family members by ABT-737. For ex-
ample, ectopic expression of NOXA prevents MCL-1
sequestering BIM [41]. ABT-737 itself also increases ex-
pression of NOXA in some cells [41] but whether this is
a significant and frequent phenomenon is debateable be-
cause if it were it would prevent MCL-1 from conferring
resistance to ABT-737.
The expression of NOXA is increased following expos-
ure to several chemotherapeutic agents and conse-
quently NOXA is implicated in the synergy between
these drugs and ABT-737. The importance of NOXA ex-
pression is demonstrated by several observations in
which synergy between ABT-737 and chemotherapeutic
agents is reduced if the expression of NOXA is repressed
using RNAi. Repression of NOXA reduces synergy be-
tween ABT-737 and temozolomide [42], etoposide
[27,43], vinblastine [27], cisplatin [43], CPT-11 [44] and
oxaliplatin [45]. NOXA is also necessary for synergy
with the proteasome inhibitors bortezomib [44] and
MG132 [28].
BIM
Early work in the field highlighted the importance of the
association of BIM with BCL-2 in determining sensitivity
to ABT-737 [46]. Cancer cells from a number of lymph-
oid malignancies show significant (IC50 < 100 nM) sensi-
tivity to ABT-737 as a single agent. In these cells, BCL-2
is already primed with BIM [8,47,48]. However, if BIM isassociated with MCL-1, the cells are resistant to ABT-
737 unless NOXA is also expressed and occupies MCL-
1 [18]. Thus, the apoptosis inhibitor to which BIM is
bound as well as which other BH3-only proteins are
expressed helps determine sensitivity to ABT-737. Re-
sistance to ABT-737 may also result from reduced ex-
pression of BIM. Small cell lung cancer (SCLC) cells
grown as xenografts that have developed resistance to
ABT-737 show a reduction in BIM:BCL-2 complexes
compared to sensitive cells [49]. These observations
underline the multi-parametric nature of sensitivity to
ABT-737, and emphasize the complexity of its accurate
estimation in personalized medicine.
Several chemotherapeutic agents induce the expres-
sion of BIM and probably priming of the apoptosis
inhibitors with BIM. ABT-737 disrupts complexes of
BIM and BCL2 (in some cells, docetaxel appears to
induce priming of BCL-2 with BIM), and ABT-737
and docetaxel in combination show improved activity
against the same cells grown as xenografts, compared
to the activity of either agent alone [50]. Similarly, the
displacement of BIM from BCL-2 by ABT-737 contri-
butes to synergy observed between ABT-737 and
TRAIL [51]. Thus, the use of ABT-263 in persona-
lized medicine in combination with other cancer ther-
apeutics offers yet more challenges in accurately
predicting patient response because of the response to
drug exposure.PUMA
Recent work has suggested that PUMA functions as a
direct activator of BAX and BAK [2-4]. In the presence
of ABT-737 to occupy apoptosis inhibitors, the expres-
sion of PUMA may be sufficient to induce apoptosis [4].
PUMA co-operates with other BH3-only activators and
ABT-737 to induce apoptosis [52] while loss of PUMA
reduces the apoptotic activity of ABT-737 [2,4].BID
BID is a BH3-only activator whose caspase-mediated
cleavage promotes its pro-apoptotic activity. ABT-737
has been shown to trigger the cleavage of BID in leukae-
mia [53] and neuroblastoma cells [54]. Cleavage of BID
is observed following activation of the extrinsic apop-
tosis pathway, so how is this enhanced by ABT-737?
This could reflect cross-talk between the intrinsic and
extrinsic apoptosis pathways, or we speculate it may be
linked to the up-regulation of the TRAIL receptor DR5
by ABT-737 [55]. From a personalized medicine per-
spective, this raises the question whether it is important
to consider both the extrinsic as well as the intrinsic
apoptosis pathway when predicting patient response to
ABT-263.
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BAD is classified as a BH3-only sensitizer, and so its lib-
eration by ABT-737 indirectly induces apoptosis by re-
ducing the reservoir of apoptosis inhibitors. BAD and
ABT-737 bind to the same apoptosis inhibitors suggest-
ing that expression of BAD would be anticipated to re-
duce the concentration of ABT-737 required to occupy
BCL-2/BCL-XL/BCL-W. However, there is additional
complexity because by preventing the association of
BAD with BCL-XL, ABT-737 slows the turnover of BAD,
leading to a striking increase in BAD protein [56]. The
relative contributions of BAD prior to, and after, expos-
ure to ABT-737 remain unclear.
Summary of factors affecting sensitivity
From the foregoing discussion, it is clear that there is no
single determinant of sensitivity to ABT-737. In several
cases, various BH3-only proteins have been identified as
being “necessary” for ABT-737 to exhibit pro-apoptotic
activity. Discrepancies between different studies prob-
ably reflect differences in the experimental setting:
whether cells are primed; the genetic background of the
cells being studied; the BH3-only proteins and the apop-
tosis inhibitors expressed and the effect of ABT-737 on
their expression. The over-arching factor that deter-
mines whether ABT-737 induces apoptosis appears to be
whether sufficient BH3-only proteins can be released to
exceed the buffering capacity of the apoptotic inhibitors
when cells are exposed to ABT-737. This is determinedFigure 3 Strategies to decrease the expression of MCL-1. The sensitivit
expression of MCL-1. The ERK (including RAF and MEK) and PI 3-kinase pat
pathway show synergy with ABT-737. Drugs inhibiting other regulators of M
ABT-737. ARC, 4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7 H-pyrrolo(2,3-d
ROS, reactive oxygen species; SFK, SRC family kinase. For references, the reaby the repertoire of apoptosis inhibitors, BH3-only acti-
vators and sensitizers expressed in a particular cell. As
we will discuss below, this creates a significant dilemma
for predicting drug sensitivity in the clinic. Analysis of
protein expression alone may not be sufficient to under-
stand the drug sensitivity of an individual tumor, rather
measurement of the functional status of the intrinsic
apoptosis pathway may be a superior predictor.
Strategies for overcoming resistance to ABT-737
One aspect of personalized medicine envisages that
patients may not receive a drug where assessment of the
molecular abnormalities in their tumor predicts that the
drug is unlikely to be effective. But through an under-
standing of the pathways regulated by ABT-737 and
ABT-263, can we rationally design drug combinations
which increase the sensitivity of cells to these drugs?
This may benefit patients predicted to be unresponsive
to ABT-263. Two general strategies have been advanced,
categorized as either decreasing the expression of MCL-
1, or increasing the expression of BH3-only proteins, or
in some cases both of these factors are involved.
Decreasing the expression of MCL-1
The observation that MCL-1 can confer resistance to
ABT-737 suggests that strategies to decrease the expres-
sion of MCL-1 might increase sensitivity to ABT-737.
Several drugs have been proven effective in preclinical
studies (Figure 3). This approach is also particularlyy of cells to ABT-737 can be increased using drugs which decrease the
hways are key regulators of MCL-1 expression so drugs inhibiting this
CL-1 are also shown, and these drugs also increase sensitivity to
)-pyrimidine-5-carboxamide; CTX, chemotherapy; EGF-R, EGF receptor;
der is referred to the main text.
Stamelos et al. Journal of Molecular Signaling 2012, 7:12 Page 7 of 15
http://www.jmolecularsignaling.com/content/7/1/12important because exposure to ABT-737 can itself in-
crease expression of MCL-1 [16,35,36] thus providing a
mechanism by which resistance to ABT-737 can be
caused by the drug itself.
Activation of the MAP-kinase (ERK) signalling cas-
cade increases levels of MCL-1 through increased
transcription [57] and increased protein stability [58].
Consequently inhibition of components of this cas-
cade increase sensitivity to ABT-737. This appears to
be a particularly important locus for intervention, be-
cause exposure to ABT-737 activates the MAP-kinase
pathway [59], and increases expression of MCL-1
[31,34,53,60,61]. Thus, repression of the ERK pathway
through inhibition of RAF with sorafenib or inhibition
of MEK reduces levels of MCL-1 and is synergistic
with ABT-737 in vitro [59,62,63]. ABT-737 combined
with a MEK or RAF inhibitor is more effective in
xenograft studies than the single agents [31,59,63].
Dasatinib is an inhibitor of BCRABL and SRC-family
kinases. In haematological malignancies, dasatinib has
been shown to inhibit SRC-family kinase-mediated acti-
vation of the transcription factor STAT5, and corres-
pondingly decrease the expression of MCL-1 [40,64-66].
Dasatinib also reduces the expression of MCL-1 by inhi-
biting the SRC-family kinase LYN which suppresses the
expression of miR-181. This microRNA recognizes the
MCL-1 3’ UTR [67], decreasing expression of MCL-1
and contributes to the synergy between dasatinib and
ABT-737 in CLL cells [40]. As LYN is widely expressed,
it will be of interest to evaluate this strategy in other
cancers. Synergy between ABT-737 and two other
BCRABL inhibitors, imatinib and nilotinib, that are used
in the treatment of CML has also been reported [68-71].
In part, this synergy may also reflect reduction of MCL-
1 by imatinib [72]. This is of particular interest because
resistance to imatinib can lead to treatment failure. Po-
tential mechanisms of resistance to imatinib include
increased expression of the apoptosis inhibitors [68,71]
or diminished expression of BH3-only proteins [71].
This offers the prospect of combining ABT-263 with
BCRABL inhibitors to treat CML.
The PI3-KINASE pathway is frequently activated in
cancer, leading to activation of AKT and several down-
stream effectors. Amongst these is mTORC1 which reg-
ulates 5’ cap-dependent mRNA translation through
phosphorylation of 4EBP1. This is particularly important
because the short half-life of MCL-1 suggests that inter-
fering with MCL-1 protein synthesis should have a dra-
matic effect on expression levels. Examples of inhibition
at several points on the PI 3-KINASE/AKT/mTORC1
pathway and its impact on MCL-1 are discussed below,
although it is important to note that factors other than
regulation of MCL-1 synthesis may contribute to the im-
pact on protein level.GDC-0941 is a PI 3-KINASE inhibitor which reduces
the expression of MCL-1[35]. In part, this reflects the in-
duction of BH3-only proteins which may promote turn-
over of MCL-1. GDC-941 and ABT-737 synergistically
induce cell death in vitro and in combination inhibit
xenograft growth [35]. Importantly, ectopic expression
of MCL-1 reduces this effect of the drug combination.
Inhibition of other members of the PI 3-KINASE signal-
ling pathway also provides potential routes for increasing
sensitivity because inhibition of AKT or mTORC1 is also
synergistic with ABT-737 [73,74].
MCL-1 expression is maintained in the presence of
extracellular glucose, but it rapidly diminished in its ab-
sence. Inhibition of glycolysis with 2-deoxyglucose (2-
DG) can also inhibit the expression of MCL-1 [75,76].
This may in part be mediated through regulation of pro-
tein synthesis by the PI 3-KINASE/AKT/mTORC1 path-
way. Inhibition of glucose metabolism and consequently
mTORC1 reduces phosphorylation of 4EBP1 and
decreases expression of MCL-1 [75,76]. However, activa-
tion of this pathway by constitutively active AKT is not
sufficient to maintain the expression of MCL-1 in the
absence of extracellular glucose [75], suggesting that glu-
cose regulates MCL-1 expression through more than
one pathway. Nonetheless, resistance to ABT-737 could
be overcome by inhibition of glycolysis with 2-DG or
mTORC1 with PP242 [75]. In other cells, 2-DG does
not substantially reduce expression of MCL-1, but it
does block its ability to form a complex with BAK [37].
Furthermore, the combination of 2-DG with ABT-737
or ABT-263 improved the survival of animals with an
experimental model of lymphoma [77] or prostate can-
cer [37] beyond that seen in animals treated with either
agent alone.
PIM kinases are also involved in the regulation of tran-
scription, translation, cell survival and energy metabol-
ism [78], including regulation of phosphorylation of
4EBP1. Of particular interest, inhibition of PIM kinases
decreases translation of MCL-1 mRNA, as well as in-
creasing degradation of MCL-1 protein [33]. The
reduced level of MCL-1 (as well as up-regulation of
NOXA, see below) is thought to underlie the more than
additive activity seen with a PIM inhibitor and ABT-737
both in vitro and in xenograft studies [33].
CDK9 is part of the transcription elongation factor b
complex that regulates elongation of mRNA [79]. ARC
is a nucleoside analogue which inhibits CDK9 and
reduces the expression of MCL-1 [80]. In combination
with ABT-737, ARC induces apoptosis and causes a syn-
ergistic inhibition of cell survival. The transcription of
MCL-1 can also be reduced by exposure to roscovitine
which inhibits several cyclin dependent kinases includ-
ing CDK9 and this also increases sensitivity to ABT737
[15,24,40]. Synergy with flavopiridol, another pan-CDK
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observed [30].
Fenretinide is a synthetic retinoid whose cytotoxic ac-
tivity depends in part on the generation of reactive oxy-
gen species (ROS). Subsequent activation of JNK by
ROS leads to phosphorylation and decreased levels of
MCL-1 [53]. Synergy has been observed between fenreti-
nide and ABT-737 in acute lymphoid leukemia (ALL)
and neuroblastoma cells in vitro [53,54] and the drug
combination improves the survival of mice bearing
neuroblastoma xenografts beyond that seen with either
agent alone [54].
Several chemotherapeutic agents have shown synergy
with ABT-737 (reviewed in[10]) and in some cases this
reflects the decreased MCL-1 caused by the chemother-
apy, for example by etoposide or cisplatin [43,81]. In
other cases, the induction of the pro-apoptotic protein
NOXA may lead to the ubiquitination and proteasomal
degradation of MCL-1 [82]. However, down-regulation
of MCL-1 has also been observed without an accom-
panying increase in NOXA [43] [83], suggesting that the
chemotherapeutic agents decreased the expression of
MCL-1 through several mechanisms. The transcriptional
inhibitor actinomycin has been shown to reduce MCL-1
[29,83]. The activity of this chemotherapeutic agent is
reminiscent of the effect seen when targeted agents are
used to inhibit transcription and translation through in-
hibition of cyclin-dependant kinases, mTORC or PIM
kinases.
Other agents which have shown synergy with ABT-737
by virtue of down-regulating MCL-1 include methylseleni-
nic acid [84] and L-asparaginase [85].
Induction of BH3 proteins
An alternative to decreasing the expression of MCL-1 is
to induce BH3-only proteins to occupy MCL-1 and
hence increase sensitivity to ABT-737. Both chemothera-
peutic and molecularly-targeted agents have been used
successfully.
Induction of NOXA appears to be one key strategy to
increase sensitivity to ABT-737, because NOXA binds to
the BCL-2 family proteins MCL-1 and BFL/A1 that are in-
sensitive to antagonism by ABT-737. Consequently,
NOXA can co-operate with ABT-737 to occupy the full
repertoire of anti-apoptotic BCL-2 family inhibitors.
NOXA has also been reported to induce the degradation
of MCL-1 [82,86,87] but not in all cells [41]. NOXA is
induced by exposure to several chemotherapeutic agents
including fludarabine [40], CPT11 [88], imiquimod [25],
dacarbazine [25] and actinomycin [83] and in each of
these cases, synergy with ABT-737 has been observed. Al-
though temozolomide as a single agent does not appre-
ciably affect NOXA, its combination with ABT-737
induces NOXA, leading to a more than additive inductionof apoptosis and improved activity in a xenograft model
[42]. In several cases, the induction of NOXA appears
crucial, as inhibition of the expression of NOXA using
RNA interference reduces the effect of the drug combin-
ation [25,42,44]. Similarly, ectopic expression of NOXA
enhances the effect of the combination of actinomycin
and ABT-737 [83].
Expression of NOXA is also increased by exposure to
targeted agents including several proposed BH3
mimetics [16], bortezomib [30,40], a PIM kinase inhibi-
tor [33], and inhibition of signalling through the
NOTCH pathway using a γ-SECRETASE inhibitor [89].
NOXA appears to contribute to the synergy observed
between ABT-737 and these agents because knockdown
of NOXA reduces the effect of the drug combination
[40,89].
BIM binds to all the known apoptosis inhibitors, in-
cluding MCL-1. Inhibition of the epidermal growth fac-
tor receptor (EGFR) with erlotinib or gefitinib leads to
increased expression of BIM [46,90,91], probably
through transcriptional and translational regulation [90],
and apoptosis. In these experiments, ABT-737 exhibited
minimal activity when tested on its own, but when com-
bined with erlotinib or gefitinib, a more than additive in-
crease in cell death was observed. Combining ABT-737
with an EGFR inhibitor may avoid early resistance to
EGFR inhibitors that arises from increased BCL-2/ BCL-
XL expression [92].
These data suggest that EGFR suppresses the expres-
sion of BIM. One of the downstream pathways mediat-
ing this is likely to be the ERK (MAP) kinase pathway
because inhibition of RAF or MEK increased the expres-
sion of BIM. Sorafenib (which inhibits several kinases in-
cluding RAF) induces BIM and apoptosis and is
synergistic with ABT-737 in AML cells [93]. In AML
cells that are relatively insensitive to ABT-737 alone, a
MEK inhibitor was synergistic with ABT-737 [59]. This
synergy was dependent on BIM because suppression of
BIM by RNAi reduced apoptosis that was induced by
the drug combination. A MEK inhibitor also improved
the efficacy of ABT-737 in an AML xenograft model
[59]. In NSCLC cells, a MEK inhibitor caused predomin-
antly G1 arrest and ABT-737 on its own minimally
induced apoptosis [63]. However, when the drugs were
combined, a more than additive induction of apoptosis
was observed and the drug combination showed sub-
stantially improved activity in a xenograft models.
An inhibitor of JAK2 induced BIM and also showed
synergy with ABT-737 in cells harbouring a JAK2 acti-
vating mutation [94].
Histone deacetylase (HDAC) inhibitors have also
been shown to induce expression of BIM and the pre-
ferential priming by BIM of BCL-2 and BCL-XL than
of MCL-1. Consequently, the HDAC inhibitor suberoyl
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synergistically with ABT-737 [95]. ABT-737 released
BIM from complexes with BCL-2 or BCL-XL, and
knockdown of BIM substantially blunted the effect of
the drug combinations. Vorinostat (also known as
SAHA, another HDAC inhibitor) induces histone
acetylation, the expression of the genes encoding BMF,
BIM and NOXA and consequent priming of BCL-2
[96]. As a result, vorinostat showed synergy with ABT-
737 which was reduced by inhibition of BMF expres-
sion by shRNA.
Although BAD does not bind to MCL-1, it is possible
that it could still improve sensitivity to ABT-737 by re-
ducing the total capacity of free apoptosis inhibitors.
Both sorafenib [61,93] and ABT-737 [56] can increase
BAD protein levels. Sorafenib increased the transcription
of BAD [61] whereas ABT-737 decreased the turnover
of BAD [56]. Sorafenib also regulates BAD through in-
hibition of BAD phosphorylation, promoting its pro-
apoptotic activity. Sorafenib and ABT-737 have been
shown to display synergistic activity in a number of cell
types [61,93]. However, it is difficult to ascribe this solely
to the effect of sorafenib on BAD, because of the impact
of sorafenib on MCL-1.
BAD is also likely to play a role in the change in sen-
sitivity to ABT-737 when cells are deprived of glucose
or exposed to 2-DG (discussed above). In its unpho-
sphorylated state, BAD promotes apoptosis, but when
phosphorylated it regulates glucose metabolism [97].
Dephosphorylation of BAD is promoted by glucose
deprivation [98], suggesting that 2-DG may do the
same, and that this may contribute to the synergy
observed between ABT-737 and 2-DG. However, 2-DG
also induces the expression of BIM, BMF and NOXA
[99,100] and glucose deprivation induces PUMA, BID
and BIM [75,101], again making it difficult to assess
the contribution of BAD.
Factors that complicate measurement of
sensitivity to BH3 mimetics
The underlying goal of the work discussed in the pre-
vious section was to develop methods that can be
translated to the clinic to improve patients’ response
to ABT-737/ABT-263. This presupposes that experi-
mental measurements of the sensitivity to ABT-737
made in the laboratory are predictive of clinical out-
come. How good are our preclinical models? While
xenograft studies are considered by many to remain
the best predictors of clinical activity, they are costly
and relatively slow. This makes it crucially important
that cellular assays are as realistic as possible so that
appropriate hypotheses are tested in animal and clin-
ical studies. Perhaps the most common setting in
which sensitivity to drugs is measured uses cancer celllines growing in nutrient and growth-factor rich media
as a monolayer attached to cell culture plasticware in
21 % O2 (i.e. atmospheric oxygen). The past decade has
seen a growing appreciation that this is perhaps not
the most realistic model, although it is experimentally
convenient. In patients, tumor cells may be located
in hypoxic, nutrient-poor environments comprising 3-
dimensional tumors. Each of these factors has been
reported to affect cellular sensitivity to ABT-737.
Metabolism
Tumor cells are thought to depend more on glycolysis
than oxidative phosphorylation to provide ATP and as
we have noted, the extracellular glucose concentration
affects sensitivity to ABT-737. Metabolic factors that
influence sensitivity are not limited to carbohydrate
metabolism. Starvation of amino acids and growth fac-
tors leads to the up-regulation of PUMA [102], and its
subsequent priming of BCL-XL renders cells sensitive
to ABT-737.
ABT-737 is further linked to metabolism through its
ability to stimulate autophagy. The nucleation phase of
autophagy involves the activation of the lipid kinase
VPS34 by the BH3-only protein BECLIN. BCL-2 can se-
quester BECLIN and the release of BECLIN by ABT-737
triggers autophagy [103,104]. However, ABT-737 also
activates other regulators of autophagy including AMPK
and IKK, both of which appear to be necessary for ABT-
737 to stimulate autophagy [104]. How these factors
conspire with the pro-apoptotic activity of ABT-737 to
determine the final cellular response to ABT-737 is un-
clear, as autophagy can promote both cell survival and
cell death. Nevertheless it is clear that metabolism and
the activity of ABT-737 are intimately linked.
Hypoxia
Several reports indicate that hypoxia increases the sensi-
tivity of tumor cells to ABT-737 [105-107]. This may re-
flect down-regulation of MCL-1 [105], or up-regulation
of BH3-only proteins including PUMA, NOXA, BNIP3
or NOXA [107]. It is noteworthy that cells resistant to
anoxia show increased expression of apoptosis inhibitors
[107]. In xenograft studies, ABT-737 induces apoptosis
preferentially in hypoxic regions of the tumor [105]. Fi-
nally, the extent of synergy seen between chemothera-
peutic agents and ABT-737 is also dependent on oxygen
concentration [105]. Thus, it may be advisable to evalu-
ate ABT-737 activity in laboratory experiments under a
more physiological oxygen tension.
3-dimensional culture
An alternative to testing the sensitivity of cells in a
monolayer is to use 3-dimensional cultures such as
spheroids. These are aggregates of growing tumor cells
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mimic a small tumor. The repertoire of BCL-2 family
proteins appears to change in cells grown as spheroids,
compared to the same cell line grown as a monolayer.
Increases in the expression of BCL-2 and BCL-XL have
been observed in spheroids [108-111], and decreases in
the expression of MCL-1 has also been reported
[108,109]. This implies a switch towards an ABT-737-
sensitive phenotype in cells grown as spheroids. Thus,
even though increased resistance to either cisplatin or
the combination of bortezomib and TRAIL was
observed when cells were grown as spheroids, this could
be overcome by exposure to ABT-737 [108,109]. The ex-
pression of pro-apoptotic family members may also be
changed, and the growth of melanoma cells in spheroids
leads to reduced expression of NOXA [26] but increased
expression of BIM confers sensitivity to ABT-737 [112].
Although these observations highlight the usefulness
of spheroids as tumor models, some caution is appropri-
ate A decrease in drug sensitivity in spheroid culture
may also be due to poor diffusion of the drug into the
spheroid inner mass [26], or a reduced rate of prolifera-
tion. The changes in the expression of both pro- and
anti-apoptotic BCL-2 family members observed in
spheroids may also be linked to the oxygen gradient be-
tween the inside and outside of the spheroid [105].
These observations suggest that a more complete
understanding of tumor cell sensitivity to ABT-737
requires that we adapt our experimental condition. It is
interesting to note that in some cases ABT-737 inhibits
the growth of xenografts in animals even though this is
not predicted by experiments performed under standard
cell culture conditions [81,113]. We suggest that al-
though it is reasonable to evaluate the gross factors that
determine sensitivity to ABT-737 using standard cell cul-
ture conditions, a refined understanding will be provided
by using more complex models that recapitulate (patho)
physiological conditions more closely. The clinical evalu-
ation of the conclusions from laboratory experiments is
then more likely to have a successful outcome.
Translational impact
Which patient groups might benefit from ABT-263? In
addition to activity as monotherapy in animal models of
lung cancer [12,49,114] [11] and several lymphoid malig-
nancies [11,12,15,62,85,115], ABT-737 or ABT-263 have
also shown activity in combination with other drugs in
animal models of numerous different cancer types. This
includes the most prevalent cancers, breast [35,50], pros-
tate [37], lung [92,116-118] and colorectal cancers [45]
cancers. In principle, BH3 mimetics may improve the re-
sponse to any chemotherapeutic agent that induces
apoptosis through the intrinsic pathway. Thus, the use
of such drugs may not be limited to cancers originatingfrom particular tissues. Consequently, a key goal of clin-
ical studies with ABT-263 will be to identify which
patients should receive the drug, either alone or in com-
bination with another drug. Bearing in mind the number
of factors discussed above that influence sensitivity to
ABT-737, how can this be achieved? There remain a
number of complications which must be addressed.
Firstly, several groups have failed to demonstrate a
correlation between drug sensitivity and expression of
an individual apoptosis inhibitor [40,41,119,120]. The
discovery that MCL-1 confers resistance to ABT-737
(and presumably ABT-263) suggests that measurement
of MCL-1 could be used to exclude patients from treat-
ment with ABT-263 and instead direct the use of ABT-
263 in combination with a drug to repress MCL-1. The
predictive value of MCL-1 measurement has been
improved by measuring ratios of multiple ABT-737- sen-
sitive and insensitive apoptosis inhibitors [30,120,121].
This suggests that the expression of all the BCL-2 family
apoptosis inhibitors should be considered.
Secondly, the BH3-only proteins also influence sensi-
tivity to ABT-737. Thus, correlations between NOXA/
MCL-1 [40,41] and BIM/MCL-1 [73] ratios have been
reported. This suggests that it would be helpful to in-
clude measurement of these in any biomarker panel.
Thirdly, even measuring the expression of both apop-
tosis inhibitors and BH3-only proteins may not be ad-
equate, because some tumor cells exhibit dependency on
more than one apoptosis inhibitor for survival. For ex-
ample, cells containing BIM in complex with MCL-1
and BCL-2 may still be sensitive to ABT-737 if sufficient
BIM can be liberated from BCL-2 to induce apoptosis
[18]. Priming of the apoptosis inhibitors provides a good
correlation with clinical response to chemotherapy [122]
and the response to ABT-737 in primary cultures [47].
This suggests that determining the distribution of pro-
apoptotic proteins among the various apoptosis inhibi-
tors is likely to be a better predictor of sensitivity to
ABT-737 than simply measuring expression [18,123].
Moreover, there are discrepancies between the sensitiv-
ities of these complexes in cells to ABT-737 and those
anticipated from in vitro studies [20,21]. This suggests
that extrapolating from knowledge of in vitro binding
interactions of BH3-only proteins and apoptosis inhibi-
tors to what happens in the clinical setting may be chal-
lenging. An alternative is to use a functional measure of
the activity of ABT-263 in which the pharmacodynamic
activity of the drug is directly measured, for example
“BH3 profiling”. This provides a functional measurement
of the sensitivity of cells to ABT-737 through assessment
of the drug’s effect (or that of a peptide corresponding
to a BH3 domain) on mitochondria isolated from cancer
cells; this can also identify the apoptosis inhibitors that
cells are dependent on for survival. Importantly, this
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coming some of the difficulties discussed above. By dir-
ectly measuring the effect of the drug, it is neither
necessary to have knowledge of the expression of BCL-2
family members, nor to analyse their interactions.
Fourthly, short-term exposure to ABT-737 has also been
reported to elevate expression of MCL-1 [16,35,36], BFL/
A1 [34] as well as BAD [56,61] and NOXA [41]. Thus,
measurement of BCL-2 family members prior to drug
treatment may provide an inaccurate indicator of drug re-
sponse. It may be preferable to briefly expose patients to
ABT-263 prior to collecting malignant tissue (e.g. by bi-
opsy or surgery). This will allow for any potential effects
of the drug on the expression of BCL-2 family members
to be assessed, prior to predicting the sensitivity of the
tumor tissue to ABT-263.
Finally, we have highlighted how experimental condi-
tions can affect the sensitivity to ABT-737. Clearly any
proposed biomarkers to predict patient response
requires validation in patients, but in the present case it
appears to be particularly important to consider the
strength of the preclinical evidence prior to advancing
potential biomarkers to clinical evaluation.
These considerations raise the issue whether accur-
ately selecting subsets of patients to receive BH3 mi-
metic therapy is feasible. What does the clinical
experience with ABT-263 so far tell us? Preliminary evi-
dence for efficacy has been observed in several lymphoid
malignancies [125]. In a recent phase 1 trial in CLL,
34 % of patients showed a partial response to ABT-263
[126]. However, there was no correlation between BCL-2
expression and patient response, although a high BIM:
MCL-1 ratio (implying occupancy of MCL-1 overcoming
resistance to ABT-263) was associated with a response.
Somewhat less encouraging results were obtained in
patients with relapsed SCLC [127] where only 2.6 % of
patients showed a partial response (although drug-
induced apoptosis was more pronounced in patients
thought to express BCL-2 more highly). Importantly, in
both CLL and SCLC, BCL-2 expression is elevated in
the majority of patients yet the outcomes of the trials
are clearly distinct. Thus, these clinical studies reinforce
the notion that measuring the expression of the targets
of ABT-263 is likely to be an inadequate predictor of
response.
Considering the difficulties in predicting response that
we have discussed above, it might even be argued that
there is merit in considering using ABT-263 without
attempting to identify which patients groups are most
likely to respond. However, the lifespan of platelets is
regulated by BCL-XL which consequently is shortened by
ABT-737 [128,129]. Correspondingly, thrombocytopenia
is a major adverse effect of ABT-263 [125-127,130] which
may preclude its “non-selective” use. Patients with alreadyreduced platelets (e.g. some leukemias) may be particu-
larly at risk if treated with ABT-263. This also suggests the
possibility that drug interactions may occur in patients co-
treated with other drugs such as carboplatin that also
cause thrombocytopenia. This may limit the use of ABT-
263 in combination with carboplatin, which is unfortunate
because synergy between ABT-737 and carboplatin has
been observed in preclinical studies [113]. It is interesting
to note that Abbot have recently developed ABT-199, an
analog of ABT-263 that avoids antagonising BCL-XL that
may overcome some of these difficulties. However, this
drug is unlikely to be effective in tumors dependent on
BCL-XL rather than BCL-2 (eg ovarian cancer, [113]) and
we speculate that BCL-XL will emerge as a mechanism of
resistance to ABT-199.
Taking into account the complexities of measuring
drug sensitivity that we have discussed, our opinion is
that it would be preferable not to select patients for
entry into clinical trials of BH3 mimetics using measure-
ment of the expression of BCL-2 family members alone
(even if this includes both pro- and anti-apoptotic mem-
bers). Although there have been notable successes in
using biomarkers to identify patients who respond to a
particular drug, we doubt whether measuring expression
levels alone will identify all patients likely to respond to
ABT-263. However, some method of patient selection is
clearly desirable. We consider that assays that measure
functional outcome as the response to a drug are prefer-
able because they are independent of our assumptions
regarding factors that control drug sensitivity. One such
assay is BH3 profiling. Alternatively, we note that apop-
tosis can be measured in patients within 6 hours of
SCLC patients receiving ABT-263 [130]. We believe that
this is likely to provide a more robust prediction of drug
therapeutic activity because it measures the drug’s
anticipated pharmacological effect in patients. Such tests
evaluating the pharmacodynamic activity of ABT-263
could be used as the basis of selecting patients to receive
ABT-263. In principle, this approach could be applied
more widely in personalized medicine in oncology, where
drug-induced apoptosis is frequently a desired outcome.
Conclusion
The trend from cytotoxic chemotherapy towards tar-
geted therapeutics offers the promise of improved effi-
cacy accompanied by a reduction in the adverse effects
seen with chemotherapy. Currently, cancer therapies
take patient characteristics into consideration but with
regards to the tumor itself, other than conventional fac-
tors such as stage and histological type, traditional ther-
apy has been based on a ‘one size fits all’ approach.
While this may have been acceptable with chemother-
apy, targeted therapeutics are designed to be more se-
lective so the possibility that tumors can evade the
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we learn, the more we appreciate the complex hetero-
geneity that exists between and within tumor types.
Thus, patients are likely to be more varied in their re-
sponse to targeted therapies than to chemotherapy. The
concept of personalised medicine is an appealing solu-
tion to this problem, but demands a depth of under-
standing of disease biology that is only just beginning to
be translated from the laboratory to the clinic.
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